18F-DCFPyL(PSMA)PET作为转移性前列腺癌放疗反应评估工具
本文回顾11例寡转移性前列腺癌患者(25个转移灶)接受转移灶定向放疗后,以18F-DCFPyL PSMA PET再分期,多数病灶PSMA-PET/CT摄取缺失提示治疗反应;体外及异种移植实验显示放疗后PSMA蛋白与mRNA表达存在高度异质性,耐药细胞PSMA表达显著降低。
要点
- 多数转移灶定向放疗后病灶PSMA-PET/CT摄取缺失,提示治疗反应,即使低BED放疗亦如此。
- 人标本与异种移植瘤中PSMA表达均呈高度异质性。
- 耐药22RV1-RR与DU145-RR细胞及肿瘤较亲本PSMA转录与蛋白表达显著降低。
核心结论
- PSMA-PET可能是有前景的评估寡转移性前列腺癌放疗反应的工具。
- 未来系统研究该概念时应认识到前列腺肿瘤内PSMA表达高度异质性及放疗后存活肿瘤PSMA表达缺失的风险。
研究设计与样本
- 回顾11例寡转移性前列腺癌男性患者(25个转移灶),接受转移灶定向放疗后于二次复发时以18F-DCFPyL(PSMA)PET再分期。
- 采用qPCR与免疫印迹检测人野生型雄激素敏感(LNCap)、去势抵抗(22RV1)及去势抵抗神经内分泌(PC3、DU145)前列腺癌细胞系中放疗对PSMA蛋白与mRNA水平的急性影响。
- 对异种移植瘤行免疫组织化学分析,并检测未照射与照射后筛选存活的高剂量放疗耐药(RR)22RV1(22RV1-RR)与DU145(DU145-RR)细胞及异种移植瘤的PSMA表达。
主要发现
- 多数转移灶定向放疗后病灶PSMA-PET/CT摄取缺失,提示治疗反应,即使低生物有效剂量(BED)转移灶定向放疗后亦如此。
- 人标本与异种移植瘤中均观察到相似的高度PSMA表达异质性。
- PSMA在LNCap与22RV1细胞及肿瘤中高表达,而在神经内分泌PC3与DU145模型中不表达。
- 单次分割放疗使LNCap细胞PSMA蛋白可检测性降低但mRNA水平未降低,对其他细胞系组织培养或异种移植瘤的PSMA蛋白或mRNA水平无显著改变。
- 放疗耐药22RV1-RR细胞与肿瘤较其亲本对应物PSMA转录与蛋白表达显著降低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate Specific Membrane Antigen (PSMA) - positron emission tomography (PET) guides metastasis-directed radiotherapy (MDRT) in prostate cancer (PrCa). However, its value as a treatment response assessment tool after MDRT remains unclear. Importantly, there is limited understanding of the potential of radiotherapy (RT) to alter PSMA gene (folate hydrolase 1; FOLH1) expression. METHODOLOGY: We reviewed a series of 11 men with oligo-metastatic PrCa (25 metastasis sites) treated with MDRT before re-staging with 18F-DCFPyL (PSMA) PET upon secondary recurrence. Acute effects of RT on PSMA protein and mRNA levels were examined with qPCR and immunoblotting in human wild-type androgen-sensitive (LNCap), castrate-resistant (22RV1) and castrate-resistant neuroendocrine (PC3 and DU145) PrCa cell lines. Xenograft tumors were analyzed with immunohistochemistry. Further, we examined PSMA expression in untreated and irradiated radio-resistant (RR) 22RV1 (22RV1-RR) and DU145 (DU145-RR) cells and xenografts selected for survival after high-dose RT. RESULTS: The majority of MDRT-treated lesions showed lack of PSMA-PET/CT avidity, suggesting treatment response even after low biological effective dose (BED) MDRT. We observed similar high degree of heterogeneity of PSMA expression in both human specimens and in xenograft tumors. PSMA was highly expressed in LNCap and 22RV1 cells and tumors but not in the neuroendocrine PC3 and DU145 models. Single fraction RT caused detectable reduction in PSMA protein but not in mRNA levels in LNCap cells and did not significantly alter PSMA protein or mRNA levels in tissue culture or xenografts of the other cell lines. However, radio-resistant 22RV1-RR cells and tumors demonstrated marked decrease of PSMA transcript and protein expression over their parental counterparts. CONCLUSIONS: PSMA-PET may be a promising tool to assess RT response in oligo-metastatic PrCa. However, future systematic investigation of this concept should recognize the high degree of heterogeneity of PSMA expression within prostate tumors and the risk for loss of PSMA expression in tumor surviving curative courses of RT.
引用
- Mesci A, Ahmadi E, Ali A, et al. 18F-DCFPyL (PSMA) PET as a radiotherapy response assessment tool in metastatic prostate cancer. Clin Transl Radiat Oncol. 2023. PMID: 36713978. doi:10.1016/j.ctro.2023.100583
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。